Bruna Pellini News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Lung cancer is the leading cause of cancer deaths in the country. According to the American Cancer Society, More than 236,000 Americans will be diagnosed with lung cancer this year, and more than half will die.